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Background: Patients with invasive breast ductal carcinoma (IBDC) with metastasis have a very poor prognosis.
Little is known about the synergistic action of growth and inflammatory factors in IBDC metastases.
Methods: The expression of activated extracellular signal-regulated kinase1/2 (phosphorylated or p-ERK1/2) was
analyzed by immunohistochemistry in IBDC tissue samples from 80 cases. BT474 IBDC cell migration and invasion
were quantified using the Transwell assay. Matrix metalloproteinase (MMP)-9 expression and activity were analyzed
by RT-PCR, Western blotting and zymography. Activator protein (AP)-1 activity was measured with a luciferase
reporter gene assay. The Wilcoxon signed-rank test, Chi-square test, the partition of Chi-square test, independent
t-test, and Spearman’s method were used for the statistical analysis.
Results: Phosphorylated ERK1/2 was detected in 58/80 (72.5%) IBDC tissues, and was associated with higher TNM
stage and lymph node metastasis, but not patient age or tumor size. Individually, epidermal growth factor (EGF),
and interleukin (IL)-1β activated ERK1/2, increased cell migration and invasion, MMP-9 expression and activity, AP-1
activation in vitro and the expression of p-ERK1/2 was positively correlated with EGF expression levels, as well as
IL-1β, MMP-9 and c-fos in IBDC tissue samples. Co-stimulation with EGF and IL-1β synergistically increased ERK1/2
and AP-1 activation, cell migration and invasion, and MMP-9 expression and activity. Inhibition of ERK1/2 using
U0126 or siRNA abolished EGF and/or IL-1β-induced cell migration and invasion in a dose-dependent manner.
Conclusion: Activated ERK1/2 was associated with higher TNM stage and lymph node metastasis in IBDC. Both in
vitro and in vivo studies indicated that ERK-1/2 activation may increase the metastatic ability of IBDC cells. Growth
and inflammatory factors synergistically induced IBDC cell migration and invasion via ERK1/2 signaling, AP-1
activation and MMP-9 upregulation.
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Breast cancer is one of the most common malignancies
in women and represents 22.9% of all female cancers
worldwide [1]. Although the 5-year survival rates for
breast cancer throughout the world are generally good
[1,2], the prognosis for patients with metastases is very
poor, especially in metastatic invasive breast ductal car-
cinoma (IBDC). The processes by which metastasis
occurs in breast cancer are still poorly understood;
therefore, characterization of the precise molecular
mechanisms that regulate metastasis in breast cancer
could potentially result in a large reduction in the num-
ber of breast cancer deaths and may lead to novel treat-
ments for breast cancer.
The mitogen-activated protein kinase (MAPK) signaling
pathways have been widely studied, and contain at least
three MAPK superfamilies that regulate diverse cellular
activities. Extracellular signal-regulated kinase (ERK) is
the most essential MAPK signaling pathway and is
involved in cell growth, motility and survival [3,4]. Five
ERK homologs have been identified: ERK1, ERK2, ERK5,
ERK7 and ERK8 [5,6]. It is well established that ERK1 and
ERK2 are two of the most important regulators of cell
proliferation, growth, differentiation and migration [7,8],
and these processes are closely related to cancer cell pro-
gression. MAPK is activated by the upstream MAP2K
kinases, which in turn are activated by the MAP3K
kinases. To date, several MAP3Ks and MAP2Ks have been
identified that regulate the ERK signaling pathway, includ-
ing the MAP3Ks Raf and Mos, and the MAP2Ks, MAPK/
ERK kinase 1 (MEK1) and MEK2. ERK1/2 is a direct tar-
get of MEK1 and MEK2 [9].
ERK1/2 activation has been observed in a wide variety
of cancers, and is closely associated with the develop-
ment of human cancer and also with the migration, in-
vasion and metastasis of cancer cells [10]. Therefore, the
ERK1/2 signaling pathways are regarded as potential tar-
gets for new cancer treatments [11]. ERK1/2 is fre-
quently activated by growth factors, such as epidermal
growth factor (EGF), which leads to increased cell
growth, differentiation and migration. Although the
EGF/Raf/MEK1/2/ERK1/2 pathway has been investi-
gated with respect to cancer cell metastasis, and it is
known that the activation of ERK1/2 promotes the
growth of breast cancer cells [12], the effect of ERK1/2
signaling activation on the metastasis of invasive breast
ductal carcinoma is poorly characterized and remains of
interest.
Recently, increasing attention has been paid to the
tumor microenvironment, which has been closely asso-
ciated with carcinogenesis and metastasis [13,14]. Accu-
mulating evidence demonstrates that the cytokines
secreted by tumor cells are important components of
the tumor microenvironment. Interleukin (IL)-1β canactivate ERK1/2 in several different cell types, and can
also activate the transcription factor activator protein
(AP)-1, which may promote inflammation-associated
carcinogenesis and play a role in cancer metastasis [15].
However, the effects of ERK1/2 signaling in IL-1β-
induced inflammation-associated metastasis, and the
synergistic effect of both growth and inflammatory fac-
tors on metastasis in IBDC, have not been well studied.
In this study, the roles of ERK1/2 in IBDC metastasis,
and the function of EGF and IL-1β-induced ERK1/2-
mediated signaling, were investigated in IBDC cells. We
observed that activated phosphorylated ERK1/2 was
associated with a higher TNM stage and the presence of
lymph node metastasis in IBDC. Additionally, in vitro
studies indicated that the activation of ERK-1/2 may in-
crease the metastatic ability of IBDC cells, and in vivo
investigations in IBDC tissue samples showed that the
expression of p-ERK1/2 had good levels of correlation
with the levels of EGF in addition to IL-1β, matrix
metalloproteinase (MMP-9) and c-fos (AP-1). Growth
and inflammatory factors synergistically induced IBDC
cell migration and invasion via activation of the ERK1/2
signaling pathway, leading to the activation of AP-1 and
increased matrix MMP-9 expression and activity.
Materials and methods
Tissue samples
The paraffin embedded blocks for 80 cases of invasive
breast ductal carcinomas (IBDC) were obtained from
Fuzhou General Hospital (Fuzhou, Fujian). The tissue
samples were used with the consent of all patients. This
study was approved by the Ethics Committee of Fuzhou
General Hospital.
Immunohistochemistry for phosphorylation of ERK1/2,
EGF, IL-1β, EGF plus IL-1β, MMP-9 and c-fos
To assess the level of ERK1/2 phosphorylation (p-ERK1/2)
by using immunohistochemical detection in the 80 cases
of IBDC, we used previously described methods [16], with
the use of a specific anti-p-ERK1/2 antibody (1:100 dilu-
tion, Cell Signaling Company, Danvers, MA, USA). The
staining results were assessed on a four-tier scale based on
that described by Ju and Ebert [17,18]: negative, no stain-
ing; 1+, weak staining; 2+, moderate staining; 3+, strong
staining. Staining intensities ≥1 were considered positive.
Statistical significance was evaluated by the Wilcoxon
signed-rank test, Chi-square test and the partition of Chi-
square test. To assess the level of EGF, IL-1β, EGF plus
IL-1β, MMP-9 and c-fos in IBDC tissues by immunohisto-
chemistry (IHC), we used the same method described
above. Anti-MMP-9 and c-fos antibodies used for IHC
were from Abcam (Cambridge, MA, USA); Anti-human
IL-1β and EGF antibodies were from Santa Cruz (Santa
Cruz, CA, USA) and Biosynthesis Biotechnology Co.
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the correlation in expression levels of p-ERK1/2 with EGF
plus IL-1β, MMP-9 or c-fos in IBDC tissue samples.
Cell culture and transfection with siRNA
BT474 cells (American Type Culture Collection, Manassas,
VA) were grown in RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal bovine serum
(FBS) at 37°C in an incubator containing 5% CO2.
SiRNA against ERK1/2 (Cell Signaling) or control siRNA
(scrambled sequence siRNA was used as nonsilencing
control siRNA) (Cell Signaling) was transfected into cells
with Lipofectamine 2000 according to the manufacturer’s
instructions.
Western blotting for ERK1/2 and MMP-9
Western blotting for the expression of ERK1/2, p-ERK1/
2 and MMP-9 in BT474 cells was conducted using pre-
viously described methods [19,20]. Briefly, 12% SDS-
PAGE was used to detect the proteins. After the proteins
were transferred onto PVDF membranes (Amersham
Bioscience, Piscataway, NJ, USA) and incubated with the
rabbit anti-human ERK1/2 or p-ERK1/2 (1:1,000 dilu-
tion, Cell Signaling) or mouse anti-human MMP-9 anti-
body (1:1,000 dilution, Abcam). The primary antibody
was detected by a horseradish peroxidase-conjugated
goat anti-rabbit or mouse secondary antibody (1:2,000
dilution, Santa Cruz). The immunoreactive protein
bands were visualized with enhanced chemiluminescent
(ECL, Amersham). Anti-β-actin (1:6,000 dilution, Sigma
Company) was used as a control for the Western blots.
Cell migration and invasion assay
For the invasion assay of BT474 cells, we used methods
described by Sumida et al. [21]. Millicell Hanging Cell
Invasion Chambers with 8-μm pore filter (Millipore Cor-
poration) were coated with 12 μL of ice-cold Matrigel
(7.5 mg/mL protein; Becton Dickinson Labware, Bedford,
MA). BT474 cells (50,000 per well) were added to the
upper chamber of these matrigel chambers in 200 μl
serum-free RPMI 1640 medium with 20 ng/ml human
EGF, 20 ng/ml IL-1β (R&D Systems), and both or nei-
ther. Cells were then placed into 24-well plates in RPMI
1640 medium containing 10% FBS. To evaluate the role of
the U0126 inhibitor, cells were pre-treated with the re-
agent for 3 h, and the stimulations were then performed.
To evaluate the role of ERK1/2 siRNA in cell migration
and invasion, BT474 cells were transfected with scrambled
siRNA or ERK1/2 siRNA for 36 h. Following this, the
transfected cells were seeded at a density of 50,000 per
well and then in 200 μl of serum-free medium for the
stimulation. When the 22-h incubation was completed,
cells were fixed with methanol and stained with Giemsa.
Cotton tips were used to remove the cells that remainedin the matrigel or attached to the upper side of the filter.
Light microscopy was used to count the cells on the lower
side of the filter. The assays were performed in duplicate,
and the results were then averaged.
The methods used for the migration assay were almost
the same as for the invasion assay described above, ex-
cept no matrigel was used to coat the well and the incu-
bation time was 16 h.
RT-PCR assay
Total RNA was extracted from BT474 cells with the Trizol
reagent (Invitrogen). The expression levels of MMP-9
mRNA were detected by first reverse-transcribing the
total RNA, followed by PCR with the following primers:
forward, 50- CAGTCCACCCTTGTGCTCTTC-30, re-
verse, 50- TGCCACCCGAGTGTAACCAT -30 for MMP-
9. The expression levels of GAPDH mRNA in each sample
were used as controls, and primers used for amplification




MMP-9 protease activities in the concentrated super-
natant medium of BT474 cells were detected by zymo-
graphy. Briefly, 8% SDS-PAGE containing gelatin
zymogram gels (Applygen Technologies Inc, Beijing,
China.) were used to separate the proteins with electro-
phoresis. Renaturing and developing the gels were per-
formed according to the manufacturer’s instructions,
and the gels were then stained with Coomassie blue.
AP-1 luciferase reporter gene assay
BT474 cells were transfected with AP-1 luc vector (1 μg)
or AP-1 luc vector plus scrambled siRNA (50–200 nM)
or ERK1/2 siRNA (50–200 nM) with Lipofectamine
2000. B-gal plasmid (containing–galactosidase reporter
gene) was co-transfected with AP-1 reporter plasmids to
serve as the control for transfection efficiency. Thirty-six
hours after transfection, the cells were left untreated or
were treated with 20 ng/ml of EGF, IL-1β or both for 12
h. The luciferase assay (for AP-1) and enzyme assay (for
B-gal) were then performed according to the instruc-
tions of the Promega kit (Madison, WI, USA).
Statistical analysis
Statistical significance of IHC for p-ERK1/2 was evalu-
ated by the Wilcoxon signed-ranks test, Chi-square test,
and the partition of Chi-square test. Spearman’s method
was used to analyze the correlation in expression levels
of p-ERK1/2 with EGF plus IL-1β, MMP-9 or c-fos in
IBDC tissue samples. For other experiments, values are
expressed as means ± SD, and independent-sample
t-tests were performed to determine differences among
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Results
Expression of phosphorylated ERK1/2 in invasive breast
ductal carcinoma
Activated ERK1/2 (p-ERK1/2) has been shown to be
expressed in many different human cancers [22], and is
likely to play a role in cancer cell growth and metastasis.
To investigate whether p-ERK was expressed in IBDC,
and to analyze the relationship between the expression
of p-ERK and the clinicopathological features of IBDC,
paraffin-embedded tissues from 80 cases of IBDC wereFigure 1 Detection of p-ERK1/2 expression in IBDC and non-neoplast
or very weakly expressed in non-neoplastic breast ductal cells (A), but was
(B to D). B to D represented different intensities of p-ERK1/2 positive stainin
expanded on the right at ×200.examined by IHC using an antibody specific for
p-ERK1/2. Positive p-ERK1/2 staining was detected in
both the cytoplasm and nucleus of IBDC cells (Figure 1).
p-ERK1/2 was positively expressed in 58/80 cases of
IBDC (72.5%, Table 1) compared to 11/80 (13.75%) of the
non-neoplastic tissues (P < 0.05, Wilcoxon signed-rank
test). The expression of p-ERK1/2 was not correlated
with patient age or tumor size; however, the expression
of p-ERK1/2 was closely associated with higher TNM
stage and lymph node metastasis in IBDC (Table 1).
There was no significant difference in the expression
of p-ERK1/2 in tumors ≥3 cm (23/33, 69.7%), those sized
<3 cm (35/47, 74.5%; P > 0.05, Chi-square test), or theic tissues using immunohistochemistry. P-ERK1/2 was not detected
frequently expressed in both the cytoplasm and nucleus of IBDC cells
g in IBDC. Images in the left panel were ×100 magnification; and
Table 1 Immunohistochemical detection of phospho-








Total 80 58 (72.5) 22 (27.5) <0.05
Age >0.05
<50 47 36 (76.6) 11 (23.4)
≥50 33 22 (66.7) 11 (33.3)
TNM staged <0.05
T1 28 16 (57.14) 12 (42.86) T1:T2+T3,
P<0.05
T2 43 34 (79.07) 9 (20.93)
T3 9 8 (88.89) 1 (11.11)
Tumor size* >0.05
≥3 cm 33 23 (69.7) 10 (30.3)




Positive△ 44 40 (90.9) 4 (9.1)
Negative 36 18 (50) 18 (50)
* Tumor size was expressed as length × width; tumors with length or width ≥3
cm were classified as >3 cm; tumors with both length and width <3 cm were
classified as <3 cm.
Δ Patient with at least one positive lymph node.
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(36/47, 76.6%; P > 0.05, Chi-square test). The expression
of p-ERK1/2 varied significantly with TNM stage (P <
0.05, Chi-square test). p-ERK1/2 expression was detected
in all three TNM stages, and was more frequent in stage
T2 and T3 tumors than T1 tumors (P < 0.05, partition
of Chi-square test). p-ERK expression was significantly
different in the tumors of patients with and without
lymph node metastasis (P < 0.01, Chi-square test), which
indicated that the expression of p-ERK1/2 correlates
with metastasis and poorer prognosis in IBDC.
EGF-induced ERK1/2 activation and IBDC cell migration
and invasion can be attenuated by ERK1/2 siRNA or
U0126
Growth factors can activate ERK1/2, and ERK1/2 activa-
tion is closely related to cancer cell migration and inva-
sion, which may be regulated by the upstream kinase
MEK1/2 via the growth factor-induced metastasis-
associated pathway [23]. Therefore, we investigated the
function of the representative growth factor, EGF and
ERK1/2 signaling, in IBDC cells. BT474 cells were stimu-
lated with EGF for 30 min. As expected, EGF-induced
ERK1/2 activation was demonstrated by the detection of
p-ERK1/2 in the cells (Figure 2A).
To determine whether EGF affects the migration and in-
vasion of IBDC cells via ERK1/2 signaling, BT474 cells
were treated with EGF in the presence or absence ofERK1/2 siRNA or the MEK/ERK pathway inhibitor,
U0126. The Transwell migration assay revealed that EGF
increased the migration and invasion of the cells; however,
EGF-induced BT474 cell migration and invasion were sig-
nificantly attenuated in a dose-dependent manner by the
knockdown of ERK1/2 using 50–200 nM ERK1/2 siRNA
(Figures 2C, E and F). Similarly, U0126 significantly
decreased EGF-induced cell migration and invasion in a
dose-dependent manner (Figures 2E and F). These data
strongly indicated that ERK1/2 plays an important role in
growth factor-induced IBDC cell migration and invasion,
and demonstrated that ERK1/2-mediated IBDC cell mi-
gration and invasion are regulated by MEK1/2.
IL-1ß-induced ERK1/2 activation and IBDC cell migration
and invasion can be attenuated by ERK1/2 siRNA or
U0126
It is established that inflammatory microenvironment
signaling plays an important role in cancer progression,
including tumor metastasis [24]. ERK1/2 are essential
molecules associated with cancer metastasis. Many pre-
vious studies have focused on the role of ERK1/2 in
growth factor-induced metastasis; however, ERK1/2 can
also be partially activated by pro-inflammatory factors
[13]. The contribution of ERK1/2 to inflammatory signal
pathway-mediated metastasis has not been well studied.
In order to understand the role of ERK1/2 in inflamma-
tory factor-induced IBDC cell metastasis, BT474 cells
were treated with the major cytokine IL-1β. IL-1β has
been reported to activate ERK1/2 in several cell types,
including cancer cells [25,26]. As expected, IL-1β acti-
vated ERK1/2, as p-ERK1/2 could be detected in BT474
cells 30 min after IL-1β stimulation (Figure 2B).
To examine the contribution of IL-1β to IBDC cell mi-
gration and invasion, BT474 cells were treated with or
without IL-1β. Increased cell migration and invasion were
observed in cells treated with IL-1β. Transwell assays
demonstrated that knockdown of ERK1/2 expression
using siRNAs attenuated IL-1β-induced cell migration
and invasion in a dose-dependent manner (Figures 2E
and F). The MEK/ERK inhibitor U0126 also significantly
inhibited IL-1β-induced BT474 cell migration and inva-
sion (Figures 2E and F), indicating that IL-1β-induced
IBDC cell metastasis are dependent on the MEK/ERK sig-
naling pathway, and also that ERK1/2 contributes to in-
flammatory factor-associated IBDC cell migration and
invasion.
EGF and IL-1β synergistically promote ERK1/2-mediated-
IBDC cell migration and invasion
Our results provided strong evidence to suggest that
both growth factor and inflammatory factor stimulation
could increase IBDC cell migration and invasion; how-
ever, it was not clear whether growth and inflammatory
Figure 2 EGF and IL-1β synergistically promote ERK1/2-mediated IBDC cell migration and invasion. A: Increased expression of activated
ERK1/2 was detected in BT474 cells after stimulation with EGF. Western blotting demonstrating that pre-treatment with U0126 significantly
inhibited EGF-induced ERK1/2 activation in BT474 cells. B, Increased expression of activated ERK1/2 was detected after the stimulation of BT474
cells with IL-1β. Western blotting demonstrating that pre-treatment with U0126 significantly inhibited IL-1β-induced ERK1/2 activation in BT474
cells. C, Western blots confirmed that the transfection of ERK1/2 siRNA dose-dependently reduced ERK1/2 expression in BT474 cells. D, Stronger
activation of ERK1/2 was detected in EGF plus IL-1β-stimulated BT474 cells (an approximate 2- to 3-fold increase) compared to EGF or IL-1β alone.
ERK1/2 siRNA and U0126 inhibited both EGF and IL-1β-induced ERK1/2 activation. E and F, Increased numbers of migrating and invading BT474
cells were observed after stimulation with EGF plus IL-1β, leading to a 2-fold increase compared to either EGF or IL-1β alone. ERK1/2 siRNA and
U0126 inhibited EGF plus IL-1β-induced cell migration and invasion. G, Representative light microscopy images of BT474 cell migration and
invasion in the Transwell assay. ** and ▼▼, P < 0.05 vs. siRNA negative control-transfected cells stimulated with EGF plus IL-1β; ΔΔ and ◇◇,
P < 0.05 vs. untransfected cells stimulated with EGF plus IL-1β. Bars are the mean ± SD of migrating and invading cells. Cells were counted as
the number of cells per field of view.
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cells were stimulated with 20 ng/mL EGF plus 20 ng/mL
IL-1β. As shown in Figure 2D, a two to three-fold in-
crease in p-ERK1/2 expression was detected when cells
were co-stimulated with both EGF and IL-1β, compared
to either EGF, or IL-1β alone. Activation of ERK1/2 by
EGF or IL-1β was almost completely blocked by ERK1/2
siRNA or the MEK/ERK pathway inhibitor U0126. Co-
stimulation with EGF and IL-1β significantly increased
the migration and invasion of BT474 cells by a factor of
about two-fold, compared to cells treated with either
EGF or IL-1β alone (Figures 2E and F). Representative
light microscope images of BT474 cell migration and
invasion in the Transwell assay were displayed in
Figure 2G.EGF and IL-1β synergistically upregulate MMP-9 in IBDC
cells via the ERK1/2 pathway
Many studies have demonstrated that the upregulation of
MMP-9 is associated with increased cancer cell migration
and invasion [27]. To test whether MMP-9 contributes to
ERK1/2-mediated IBDC cell metastasis in response to
EGF or IL-1β, RT-PCR, Western blotting and zymography
assays were performed to detect the expression and activ-
ity of MMP-9 in BT474 cells. As expected, EGF increased
MMP-9 expression and enzymatic activity in the cells, as
demonstrated by the increased expression of MMP-9
mRNA, protein and disappearance of the MMP-9 sub-
strate bands in the zymography assay. The knockdown of
ERK1/2 by siRNA or the inhibition of ERK1/2 activation
by U0126 significantly reduced EGF-induced MMP-9
Figure 3 (See legend on next page.)
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Figure 3 EGF plus IL-1β synergistically upregulate MMP-9 in IBDC cells via the ERK1/2 pathway. A, RT-PCR showing that MMP-9 mRNA
was expressed in BT474 cells and increased after EGF treatment. Knockdown of ERK1/2 using siRNA or pre-treatment with U0126 dose-
dependently attenuated EGF-induced MMP-9 mRNA upregulation in the cells. B, Bars indicate the relative expression levels of MMP-9 mRNA
normalized to GAPDH mRNA. ** P < 0.05 vs. control siRNA-transfected cells stimulated with EGF; ΔΔ P < 0.05 vs. untransfected cells stimulated
with EGF. C, IL-1β also increased MMP-9 mRNA expression in BT474 cells; EGF plus IL-1β synergistically increased MMP-9 expression compared to
either EGF or IL-1β stimulation alone; this effect could be inhibited by ERK1/2 siRNA or pre-treatment with U0126. D, Bars indicate the relative
expression levels of MMP-9 mRNA normalized to GAPDH mRNA. ** and ▼▼, P < 0.05 vs. siRNA negative control-transfected cells stimulated with
EGF plus IL-1β; ΔΔ and ◇◇, P < 0.05 vs. untransfected cells stimulated with EGF plus IL-1β. E, EGF plus IL-1β synergistically increased MMP-9
expression compared to either EGF or IL-1β stimulation alone as analyzed by Western blotting. F to H, MMP-9 activity was analyzed using
zymography. F, EGF increased MMP-9 activity; this effect could be attenuated by both ERK1/2 siRNA and U0126 in the cells. G, IL-1β also increased
MMP-9 activity in BT474 cells; H, EGF plus IL-1β synergistically increased MMP-9 activity compared to either EGF or IL-1β stimulation alone.
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ner (P < 0.05 compared with control siRNA or untrans-
fected cells, independent sample t-test), and attenuated
the EGF-induced increase in MMP-9 activity (Figures 3A
to F, and H, respectively). IL-1β alone also induced the
upregulation of MMP-9 in BT474 cells; however, EGF in
the presence of IL-1β synergistically increased both
MMP-9 expression and activity by approximately 2-fold
compared to EGF or IL-1β alone (Figures 3C to E, and G
to H).
Knockdown of ERK1/2 inhibits the synergistic activation
of activator protein-1 in IBDC cells by EGF and IL-1β
The transcription factor activator protein-1 (AP-1) is
one of the most important regulators of MMP-9 expres-
sion [28]. Our data showed that both EGF and IL-1β
upregulated MMP-9, and ERK1/2 has been demon-
strated to play critical role in the regulation of AP-1 acti-
vation. In order to investigate whether the synergistic
mechanism by which EGF and IL-1β upregulated MMP-
9 via ERK1/2 was dependent on AP-1, AP-1 activation
was detected using an AP-1 luciferase reporter geneFigure 4 Knockdown of ERK1/2 inhibits the synergistic activation of A
increased the activity of an AP-1 luciferase reporter gene in BT474 cells; ho
Transfection of BT474 cells with ERK1/2 siRNA decreased EGF or IL-1β, or EG
** or ◇◇, P < 0.05 vs. control siRNA and AP-1 luc-transfected cells stimulat
AP-1 luc-transfected cells stimulated with EGF plus IL-1β; relative luciferaseassay. As shown in Figure 4, EGF treatment increased
AP-1 luciferase activity in BT474 cells, and IL-1β also
induced the activation of AP-1 in BT474 cells. The
knockdown of ERK1/2 by siRNA significantly reduced
both EGF- and IL-1β-induced AP-1 activation in a dose-
dependent manner (P < 0.05 compared with control
siRNA, independent sample t-test). Co-stimulation with
EGF and IL-1β synergistically increased AP-1 activity by
a factor of approximately 2-fold, compared to either
EGF or IL-1β stimulation alone (Figure 4), and the in-
hibition of ERK1/2 using siRNA reduced AP-1 reporter
gene activity in cells treated with EGF plus IL-1β. A
dose-dependent decrease in AP-1 luciferase activity was
detected in BT474 cells transfected with different
amounts of ERK1/2 siRNA (50–200 nM) and the AP-1
luciferase reporter gene plasmid (Figure 4).
Relationship between of the expression level of p-ERK1/2,
EGF plus IL-1β, MMP-9 and AP-1 in IBDC tissue samples
In order to understand the relationship between the ex-
pression of p-ERK1/2 with proteins of interest in IBDC
tissue samples, IHC was used to assay the expression ofP-1 by EGF and IL-1β in IBDC cells. EGF and IL-1β stimulation
wever, EGF plus IL-1β synergistically increased AP-1 luciferase activity.
F plus IL-1β-induced AP-1 activation in a dose-dependent manner.
ed with EGF or IL-1β alone; ▼▼ and ΔΔ, P < 0.05 vs. control siRNA and
activity was normalized against B-gal.
Figure 5 The expression of p-ERK1/2 was closely related to EGF with IL-1β, MMP-9 and AP-1 in IBDC tissue samples. A, Strong
expression levels of EGF, IL-1β, and EGF plus IL-1β, stronger expression of p-ERK1/2, MMP-9 and c-fos in IBDC tissue sample. B, Weaker expression
levels of EGF, IL-1β, and EGF plus IL-1β, weaker expression levels of p-ERK1/2, MMP-9 and c-fos in IBDC tissue sample.
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AP-1(c-fos). The representative IHC results from two
cases of IBDC were displayed in Figure 5. As shown in
Figure 5, though the expression of p-ERK1/2 correlated
with the levels of EGF alone (r=0.638, p<0.01) or IL-β
alone (r=0.564, p<0.05), the expression of p-ERK1/2
correlated well with levels of IL-1β plus EGF, in
addition to MMP-9 and c-fos. There was a significant
correlation between increasing p-ERK1/2 expression
levels and the elevated expression of EGF plus IL-1β,
MMP-9 or c-fos in IBDC tissue samples (r = 0.83,
p<0.001; r=0.86, p<0.001 and r=0.77, p<0.001, respect-
ively). The data demonstrated that higher levels of EGF
with IL-1β positively correlated with increased levels of
p-ERK1/2, MMP-9 and c-fos expression in IBDC
in vivo.
Discussion
In the present work, we demonstrate for the first time
that p-ERK1/2 may be involved in the metastasis of
IBDC. Additionally, growth and inflammatory factors
may synergistically induce IBDC metastasis by increas-
ing cell migration and invasion via the activation of
ERK1/2 signaling, due to the AP-1-dependent upregula-
tion of MMP-9.
ERK1/2 are important regulators of progression and
metastasis in a variety of cancers via the MEK/ERK/AP-
1 signaling pathway [23,28]. However, it remains unknown
as to whether ERK1/2 plays a role in IBDC metastasis.
In this study, we detected the expression of activatedERK1/2 in the majority of IBDC tissue samples using
IHC assays, and found that the expression of p-ERK1/2
was closely related with a higher TNM stage and the
presence of lymph node metastasis. Therefore, activated
ERK1/2 may correlate with a poorer prognosis in IBDC.
Karroum et al. previously reported that the expression
of activated ERK1/2 was associated with cell migration
and the formation of a tubular network of resistant
MCF-7 breast cancer cells via a mechanism linked to
the activation of MMP-9 [29].
The involvement of growth factors in cancer growth
and metastasis has been widely documented. However,
little is known about the role of inflammatory signal-
ing pathways in metastasis, or the combined action of
growth factors and inflammatory factors in IBDC
cells. To gain an insight into the function of growth
factors and inflammatory factors in IBDC metastasis,
the representative growth factor, EGF, which can acti-
vate ERK1/2, and one of the most common inflam-
matory factors, IL-1β, were investigated. Consistent
with previous results in other cancer cell lines, EGF
increased IBDC cell migration and invasion via a
mechanism regulated by ERK1/2. Importantly, we also
demonstrated for the first time that IL-1β also
enhanced IBDC cell migration and invasion, and the
presence of EGF and IL-1β synergistically increased
IBDC cell migration and invasion via the ERK1/2
pathway. Therefore, ERK1/2 signaling plays an im-
portant role in inflammatory factor-associated IBDC
cell migration and invasion.
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firmed that the inhibition of ERK1/2 signaling using the
MEK1/2 inhibitor, U0126, or ERK1/2 siRNA significantly
attenuated EGF-induced cancer cell migration and inva-
sion in a dose-dependent manner. The breakdown of the
extracellular matrix (ECM) is a crucial step during the
metastatic process [31], and many studies have shown
that MMPs play an important role in ECM degradation
[30,31]. It is well known that ERK1/2 mediates cancer
cell metastasis by regulating MMP-9 expression and ac-
tivity. MMP-9 is one of the most important MMPs and
is closely related to cancer invasion and metastasis as a
result of its strong ECM proteolytic activity [27,28].
MMP-9 induces cell migration and invasion by degrad-
ing collagen in the basement membrane, which allows
cancer cells to detach from the ECM and invade sur-
rounding tissues. In this study, we demonstrated that
EGF, in combination with IL-1β, induced IBDC cell mi-
gration and invasion via the activation of ERK1/2, which
increased the expression and activation of MMP-9. The
role of ERK1/2 in this process was confirmed by the fact
that both siRNAs against ERK1/2 and the ERK/MEK in-
hibitor attenuated EGF and IL-1β-induced cell migration
and invasion.
ERK1/2 is well characterized as a serine/threonine
protein kinase that regulates the activation of the tran-
scription factor, AP-1 [32]. The activation of reporter
genes, as indicated by increased luciferase activity, is one
characteristic of gene activation in vitro. Indeed, ERK1/2
siRNA suppressed the ability of EGF and IL-1β to induce
activation of an AP-1 reporter gene, which demonstrated
that the EGF and IL-1β-induced activation of ERK1/2
led to the upregulation of MMP-9 by increasing the
transcriptional activity of AP-1. More importantly, data
from tissue samples of IBDC also confirmed that the ex-
pression of p-ERK1/2 correlated strongly with the levels
of EGF plus IL-1β, MMP-9, and c-fos (AP-1) in vivo.Conclusions
This study demonstrates that the expression of p-ERK1/
2 in IBDC is closely related to lymph node metastasis
and high tumor grade, which are indicative of poor
patient prognosis. We also showed that ERK1/2 may
functionally regulate metastasis, as growth and inflam-
matory factors synergistically increased IBDC cell migra-
tion and invasion via the ERK1/2 signaling pathway.
This led to the activation of AP-1 and the upregulation
of MMP-9. This study suggests that ERK1/2 may repre-
sent a useful therapeutic target for IBDC.
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